



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

jo

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/719,298	11/21/2003	Navroz Boghani	261088US0	2138
<div>22850 7590 06/18/2007 OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C. 1940 DUKE STREET ALEXANDRIA, VA 22314</div>				
			EXAMINER GEORGE, KONATA M	
			ART UNIT 1616	PAPER NUMBER
			NOTIFICATION DATE 06/18/2007	DELIVERY MODE ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

patentdocket@oblon.com
oblonpat@oblon.com
jgardner@oblon.com

Office Action Summary

Application No.

10/719,298

Applicant(s)

BOGHANI ET AL.

Examiner

Konata M. George

Art Unit

1616

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 03 May 2007.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-91 is/are pending in the application.
- 4a) Of the above claim(s) 38-46, 48-62 and 71-87 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-37, 47, 63-70 and 88-91 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 21 November 2003 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Claims 1-91 are pending in this application.

Drawings

1. The drawing(s) filed under 37 CFR 1.184 or 1.152 are accepted by the examiner.

Information Disclosure Statement

2. The information disclosure statement (IDS) submitted on March 19, 2004, September 27, 2004, December 27, 2004, May 20, 2005, August 23, 2005 and March 14, 2006 was noted and the submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the examiner has considered the information disclosure statement.

Restriction Requirement

3. Applicant's election with traverse of Group I, claims 1-37, 47, 63-70 and 88-91 in the reply filed on May 3, 2007 is acknowledged. The traversal is on the ground(s) that there exist no serious burden to search. This is not found persuasive because the serious burden to search lies in the different methods of use and the different compositions used which are all drawn to different classes and subclasses. The examiner would have to search different classes and subclasses to ensure a thorough and complete search of the art. Claims 38-46, 48-62 and 71-87 are withdrawn from consideration as they are directed towards non-elected claims.

The requirement is still deemed proper and is therefore made FINAL.

Double Patenting

A rejection based on double patenting of the "same invention" type finds its support in the language of 35 U.S.C. 101 which states that "whoever invents or discovers any new and useful process ... may obtain a patent therefor..." (Emphasis added). Thus, the term "same invention," in this context, means an invention drawn to identical subject matter. See *Miller v. Eagle Mfg. Co.*, 151 U.S. 186 (1894); *In re Ockert*, 245 F.2d 467, 114 USPQ 330 (CCPA 1957); and *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970).

A statutory type (35 U.S.C. 101) double patenting rejection can be overcome by canceling or amending the conflicting claims so they are no longer coextensive in scope. The filing of a terminal disclaimer cannot overcome a double patenting rejection based upon 35 U.S.C. 101.

4. Claims 1-37, 47, 63-70 and 88-91 are provisionally rejected under 35 U.S.C. 101 as claiming the same invention as that of claims 1-37, 47, 63-70 and 88-91 of copending Application No. 11/083,968. The claims of the instant invention recite the same delivery system as the claims of '968.

This is a provisional double patenting rejection since the conflicting claims have not in fact been patented.

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory

Art Unit: 1616

double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

5. Claims 1, 2, 8-10, 21 and 22 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1, 4, 5 and 8-12 of copending Application No. 11/134,356. Although the conflicting claims are not identical, they are not patentably distinct from each other because the instant invention is directed to a delivery system comprising an active component encapsulated within an encapsulating material and the copending application is a composition comprising the delivery system of the instant invention. Encapsulated delivery systems are well known in the cosmetic art for use in deodorants, foundations, etc. Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention to use an encapsulated active agent as instantly claimed in a cosmetic composition.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

6. Claims 1, 2, 5-11, 21 and 22 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1, 4-6 and 11-21 of copending Application No. 11/134,365. Although the conflicting claims are not identical, they are not patentably distinct from each other because both copending applications are directed towards a delivery system comprising an active

Art Unit: 1616

agent and an encapsulating material. The difference is that in application '365 the delivery system has a water-retention value of up to 5%, whereas the instant invention is silent with respect to water-retention value. It is the position of the examiner that since both delivery systems comprise the same active agent, encapsulating material and tensile strength, the water-retention value would also be the same and would be obvious to one of ordinary skill in the art.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

7. Claims 1-11, 21 and 22 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1, 5-7, 11-19 and 21-23 of copending Application No. 11/134,367. Although the conflicting claims are not identical, they are not patentably distinct from each other because both copending applications are directed to a delivery system comprising an active agent and an encapsulating material. The difference is that in application '367 the delivery system comprises two or more active agents. The instant invention recites that the delivery system can contain "at least one" active component. This recitation does not limit the delivery system to containing just one active component, but allows for several active components to be added if necessary and is thus obvious.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

8. Claims 1 and 8-10 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1 and 7-9 of copending Application No. 11/134,370. Although the conflicting claims are not identical, they are not patentably distinct from each other because the instant invention is directed to a delivery system comprising an active component encapsulated within an encapsulating material and the copending application is a delivery system comprising an encapsulated active component onto which an additional coating material is applied. The application of additional coatings onto particles is well known in the art for several reasons, 1) to stabilize particles, 2) for sustained or rapid release drug delivery, 3) selective target delivery of a drug. Therefore, adding an additional coating to the drug delivery system would have been obvious to one of ordinary skill in the art.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

9. Claims 1, 2, 5, 8-10 and 21 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1, 5, 6, 11-14 and 16 of copending Application No. 11/134,371. Although the conflicting claims are not identical, they are not patentably distinct from each other because both copending applications are directed to a delivery system comprising an active agent and an encapsulating material. The difference is that in application '371, the delivery system has an active component and encapsulating material are contained in a ratio of from 1:99 to 70:30, whereas the instant invention is silent with respect to water-retention

Art Unit: 1616

value. It is the position of the examiner that since both delivery systems comprise the same active agent, encapsulating material, and tensile strength, the ratio would also be the same and would be obvious to one of ordinary skill in the art.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

10. Claims 1-10, 21 and 22 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-7, 9 and 12-21 of copending Application No. 11/134,480. Although the conflicting claims are not identical, they are not patentably distinct from each other because both copending applications are directed to a delivery system comprising an active agent and an encapsulating material. The difference is that in application '480, the particles have a particles size of from about 125 to about 900 microns. Claims 19-20 of the instant invention claims particle sizes which falls within the scope of particle size as claimed in the copending application and is considered obvious.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

11. Claims 1, 2, 5, 8, 9 and 11 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1, 8-10, 12, 18 and 30-39 of copending Application No. 11/135,153. Although the conflicting claims are not identical, they are not patentably distinct from each other because both

compending applications are directed to a delivery system comprising an active agent and an encapsulating material and having a tensile strength of at least 6,500 psi. The difference is that in application '153, the delivery system has a water absorption of about 0.01 to about 50%, whereas the instant invention is silent with respect to water absorption. It is the position of the examiner that since both delivery systems comprise the same active agent, encapsulating material, and tensile strength, the water absorption rate would also be the same and would be obvious to one of ordinary skill in the art.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

12. Claims 1-5, 8, 18, 21, 22, 47 and 63-66 are rejected under 35 U.S.C. 102(b) as being anticipated by Kitajima et al. (US 3,691,090).

Kitajima et al. teach a process for the preparation of capsules containing a core material and an encapsulating material (col. 1, lines 39-41). Column 2, lines 8-15 teaches that the core material selected from foods, enzymes, medicines, etc. Column 2, lines 20-26 teach examples of the encapsulating material of which ethylcellulose, and

Art Unit: 1616

polyvinyl acetate are mentioned. Example 3 teaches a method of making aspirin containing capsules, wherein ethylcellulose is the encapsulating material. Kitajima et al. is silent with respect to the tensile strength of the particle. Tensile strength of the particle depends on the encapsulating material used. Since Kitajima et al. teach the claimed encapsulating material the limitation of tensile strength of the particle will be inherent.

13. Claims 1, 2, 5, 12, 13 and 18-20 are rejected under 35 U.S.C. 102(b) as being anticipated by Leinen (US 4,520,142).

Leinen discloses an encapsulated material comprising a liquid core and a polymeric shell material. The shell material can be a polyvinyl pyrrolidone, polyacetates, etc. (col. 2, lines 39-49). Column 2, lines 25-38 teach that the capsule could have a particle size of 5 to 75 microns. Column 2, lines 18-21 teach that the capsules should be strong enough to endure handling and spraying without rupturing but yet break under forces that can be applied by the fingernail. Leinen is silent with respect to the tensile strength of the particle. The tensile strength of the particle depends on the encapsulating material used. Since Leinen teaches the claimed encapsulating material, the limitation of tensile strength of the particle will be inherent.

Art Unit: 1616

14. Claims 1-16, 18-25, 27-32, 34-37, 47, 63-70 and 89-91 are rejected under 35 U.S.C. 102(b) as being anticipated by Schobel et al. (US 4,824,681).

Schobel et al. disclose an encapsulated sweetener (abstract). Column 5, line 55 through column 6, line 10 teach the sweetening agents which can be used in the invention. Column 6, lines 25-28 teach the particles size from about 150 to 300 microns. Column 7, lines 12-41 teaches that the coating material comprises a hydrophobic polymer and a hydrophobic plasticizer, wherein the polymer can be polyvinyl acetate phthalate and the polymer is about 55% to about 95% of the coating material. Example 1 teaches a method of making encapsulated high intensity sweetener aspartame, wherein the particles contain from 94.3% to 96.2% of the sweetener. Examples 3-6 teach a chewing gum comprising from about 1.7 to 2.7% of the encapsulated material together with additional flavoring agents. Schobel et al. is silent with respect to the tensile strength of the particle. Tensile strength of the particle depends on the encapsulating material used. Since Schobel et al. teach the claimed encapsulating material, the limitation of tensile strength of the particle will be inherent.

Conclusion

15. Claims 1-37, 47, 63-70 and 88-91 are rejected.

Art Unit: 1616


Telephone Inquiries

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Konata M. George, whose telephone number is 571-272-0613. The examiner can normally be reached from 8AM to 6:30PM Monday to Thursday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Johann Richter, can be reached at 571-272-0646. The fax phone numbers for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have question on access to the Private Pair system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Konata M. George
Patent Examiner
Technology Center 1600


Johann R. Richter
Supervisory Patent Examiner
Technology Center 1600